Paraza Pharma, a Canada based, fully integrated drug discovery organisation, announced on Monday that it has named Edward W (Ted) Marple, AB (Harvard), MBA (Virginia) as its new executive vice-president, Development.
Marple has over 20 years of experience as a senior executive with wide skill sets across clinical development, IP protection, manufacturing, operations, company and product strategy, finance, and commercial partnering/development in the biotechnology and pharmaceutical industry.
Arshad Siddiqui, Ph.D., Paraza founder and CEO, said, 'We are excited to have Ted join Paraza's senior leadership team as we continue to expand our capabilities to better serve our client-partners. Ted's extensive business and commercial expertise will be invaluable to Paraza as we continue to partner with biotechnology and pharmaceutical companies to accelerate research, development and access to new and better treatments for patients.'
Merck's sotatercept gains priority review for PAH treatment
Antibe gains approval for otenaproxesul PK/PD study
Calliditas Therapeutics' setanaxib receives US FDA orphan drug designation
Everads Therapy signs license, collaboration and supply agreement with Kriya Therapeutics
IDEAYA Biosciences' IDE161 receives US FDA fast track designation
YS Biopharma enrols first subject in Phase three PIKA Rabies Vaccine clinical trial
Armata Pharmaceuticals doses first patient in Phase 2a of AP-SA02 diSArm study
Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech
EXACT Therapeutics' ACTIVATE trial shows promise in enhancing chemotherapy efficacy
Sanofi granted Priority Review for EoE treatment in young children
Pierre Fabre Laboratories signs long-term collaboration with Vernalis (R&D)
BioArctic and Eisai secure approval for LEQEMBI infusion in Japan for Alzheimer's disease treatment